Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas | Zendy

Maria Chiara Zatelli | Zendy; Mariella Minoia | Zendy; Carlo Filieri | Zendy; Federico Tagliati | Zendy; Mattia Buratto | Zendy; Maria Rosaria Ambrosio | Zendy; Marcello Lapparelli | Zendy; M. Scanarini | Zendy; Ettore C. degli Uberti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas

Author(s) -

Maria Chiara Zatelli,

Mariella Minoia,

Carlo Filieri,

Federico Tagliati,

Mattia Buratto,

Maria Rosaria Ambrosio,

Marcello Lapparelli,

M. Scanarini,

Ettore C. degli Uberti

Publication year - 2009

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2009-1641

Subject(s) - cabergoline , somatostatin , everolimus , viability assay , endocrinology , medicine , pasireotide , pituitary tumors , apoptosis , acromegaly , chemistry , cancer research , hormone , prolactin , growth hormone , biochemistry

Pituitary adenomas can cause specific syndromes due to hormone excess and/or determine sellar mass symptoms. Pituitary cell growth can sometimes be influenced by medical therapy, such as for somatotroph adenomas treated with somatostatin analogs or prolactinomas treated with dopaminergic drugs. However, nonfunctioning pituitary adenomas (NFAs) are still orphans of medical therapy. Everolimus (RAD001), a derivative of rapamycin, is a well-known immunosuppressant drug, which has been recently shown to have antineoplastic activity in several human cancers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research